A heated bidding war has emerged in the biotech industry, with multiple companies vying to develop a promising new treatment for cancer. The competition is centered around PD-(L)1xVEGF, a bispecific antibody that combines the powers of two different targets to boost cancer-fighting abilities.
Meanwhile, news broke that Pazdur will be tapped as the next head of the FDA’s Center for Drug Evaluation and Research (CDER). This appointment comes as the agency looks to strengthen its review process and ensure that new treatments meet stringent safety standards.
Other developments in the world of biotech are worth noting. However, the details remain scarce at this time due to the ongoing nature of these discussions and negotiations.
Source: https://endpoints.news/inside-the-metsera-bidding-war-pd-l1xvegf-bispecific-race-heats-up-pazdur-tapped-as-next-cder-head-and-more